| KAI Pharmaceuticals to begin study on secondary hyperparathyroidism in ESRD ... - NephrOnline |
|
|
NephrOnline KAI Pharmaceuticals Inc. announced enrollment of the first patients in a Phase 2 study of KAI-4169, a pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism (SHPT) in end-stage renal disease patients. |